Last reviewed · How we verify
NCT03884192: CONSIST
Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC
Phase 3 trial testing Consolidation Sintilimab in Carcinoma, Non-Small Cell Lung in 162 participants. Status unknown.
30 December 2020
Quick facts
| Lead sponsor | Shandong Cancer Hospital and Institute |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 162 |
| Start date | 12 December 2018 |
| Primary completion | 30 December 2020 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Consolidation Sintilimab — full drug profile →
Conditions studied
- Carcinoma, Non-Small Cell Lung — all drugs for Carcinoma, Non-Small Cell Lung →
Sponsor
Shandong Cancer Hospital and Institute
Who can join
Adults 18 to 75, any sex, with Carcinoma, Non-Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open label, multi-center, randomized, control phase III trial, to compare the efficacy and safety of consolidation therapy with sintilimab (IBI308) versus best supported care (BSC), in unresectable stage III NSCLC patients who do not experience disease progression after initial concurrent chemoradiation.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent updates on Sintilimab in solid tumor immunotherapy.
Liu X, Yi Y. · · 2020 · cited 35× · PMID 33292551 · DOI 10.1186/s40364-020-00250-z -
Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.
Käsmann L, Eze C, Taugner J, Roengvoraphoj O, et al · · 2020 · cited 26× · PMID 32646443 · DOI 10.1186/s13014-020-01595-3 -
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.
Yang ZR, Liu MN, Yu JH, Yang YH, et al · · 2020 · cited 12× · PMID 33209626 · DOI 10.21037/tlcr-20-896 -
A Review of the Current Approach and Treatment Landscape for Stage III Non-Small Cell Lung Cancer.
Sridhar A, Khan H, Yohannan B, Chan KH, et al · · 2024 · cited 5× · PMID 38731161 · DOI 10.3390/jcm13092633 -
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.
Baudoux N, Friedlaender A, Addeo A. · · 2023 · cited 5× · PMID 36818454 · DOI 10.1177/11795549231152948 -
Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer.
Zhang X, Zhang J, Liu P, Wang J, et al · · 2023 · cited 4× · PMID 36845690 · DOI 10.3389/fonc.2023.1022042 -
Drug development and evidence for lung cancer targeted therapy in Eastern Asia.
Maggie Liu SY, Jin ZY, Deng JY, Zhong SM, et al · · 2024 · cited 2× · PMID 39381018 · DOI 10.1016/j.lanwpc.2024.101090 -
[Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics].
Radiotherapy-Immunotherapy Discussion Group, Ai X, Cai Y, Chu Q, et al · · 2020 · cited 1× · PMID 32517461 · DOI 10.3779/j.issn.1009-3419.2020.102.24
Verify or expand the search:
- PubMed search for NCT03884192
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carcinoma, Non-Small Cell Lung
Currently open trials in the same condition.
- NCT07227298 — Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer · Phase 1, PHASE2 · recruiting
- NCT06868277 — A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic · Phase 3 · recruiting
- NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
- NCT04389632 — A Study of Sigvotatug Vedotin in Advanced Solid Tumors · Phase 1 · recruiting
Other Shandong Cancer Hospital and Institute trials
Trials by the same sponsor.
- NCT07408505 — Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer · NA · recruiting
- NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
- NCT07376174 — The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted T · recruiting
- NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
- NCT07274774 — SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03884192 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Cancer Hospital and Institute
- Last refreshed: 21 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03884192.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing